Animal Antithrombin Activity Determination: Principles, Methods, and Applications

Animal antithrombin (AT) activity determination is a specialized coagulation assay that quantifies the functional capacity of antithrombin, the principal physiological inhibitor of thrombin and factor Xa, in animal plasma. This test plays a critical role in veterinary diagnostics, disseminated intravascular coagulation (DIC) monitoring, heparin therapy optimization, and preclinical thrombosis research. This article provides a comprehensive technical overview of sample requirements, testing items, analytical methods, quality standards, and practical applications of antithrombin activity measurement across animal species.

Technical Overview

Antithrombin, formerly known as antithrombin III (AT III), is a single-chain glycoprotein belonging to the serine protease inhibitor (serpin) superfamily. It is synthesized primarily in the liver and endothelial cells and circulates in plasma as the most important natural regulator of coagulation, forming irreversible 1:1 complexes with thrombin (factor IIa) and activated factor X (factor Xa). In the presence of heparin or vessel-wall heparan sulfate, the inhibitory rate of antithrombin accelerates by approximately 1,000- to 2,000-fold, which forms the pharmacological basis of heparin anticoagulation therapy.

Animal antithrombin activity determination measures the functional activity of antithrombin in animal plasma, typically expressed as a percentage of the activity found in species-specific pooled reference plasma, or in International Units per milliliter (IU/mL). Because antithrombin is consumed during thrombotic episodes, lost in protein-losing disorders, and underproduced in hepatic failure, its plasma activity serves as a sensitive indicator of coagulation homeostasis, hepatic synthetic function, and endothelial activation in animals.

Significant species and breed differences exist in antithrombin physiology. Canine, feline, equine, bovine, and rodent plasmas each require appropriately validated reference intervals. For example, healthy Greyhounds exhibit physiologically lower antithrombin activity than other dog breeds, while feline baseline values are generally lower than canine values. A rigorous determination workflow therefore incorporates species-matched calibration, validated reagent systems, and quality management consistent with ISO/IEC 17025 and ISO 15189 requirements for laboratory competence.

Testing Samples

Citrated Platelet-Poor Plasma

The specimen of choice for antithrombin activity determination is platelet-poor plasma collected into 3.2% trisodium citrate anticoagulant at a strict 9:1 ratio of whole blood to anticoagulant. Blood should be drawn by clean venipuncture to minimize tissue factor contamination and platelet activation. Following collection, samples are centrifuged at 1,500–2,500 × g for a minimum of 15 minutes to achieve a platelet count below 10,000/µL, in accordance with recognized coagulation specimen handling guidelines such as CLSI H21.

Sample Types and Sources

• Canine, feline, and equine clinical plasma submitted for diagnostic coagulation workups
• Bovine and porcine plasma collected during herd health investigations or biological product manufacturing
• Rodent (rat, mouse, guinea pig) and rabbit plasma from preclinical pharmacology and toxicology studies
• Exotic and zoo animal plasma evaluated under specialized veterinary coagulation panels
• Plasma-derived intermediates and finished biological products requiring antithrombin potency confirmation

Sample Handling, Stability, and Rejection Criteria

Antithrombin is relatively stable in citrated plasma. Samples may be held at 2–8 °C and tested within 24 hours, or frozen at −70 °C or below for longer storage, with repeated freeze–thaw cycles strictly avoided. Specimens should be rejected if clotted, markedly hemolyzed, severely lipemic, under-filled relative to the citrate volume, or suspected of heparin contamination from improper collection, since exogenous heparin may falsely alter assay response in some method formats. Each submission should be clearly identified with the animal species, breed where relevant, collection time, and clinical history to support correct interpretation.

Testing Items

Core and supplementary test items offered under animal antithrombin activity determination typically include:

• Antithrombin activity (% of species-specific pooled reference plasma, or IU/mL) — the primary functional endpoint
• Antithrombin antigen concentration (mg/dL or IU/mL) by immunologic methods, used to distinguish quantitative deficiency from functional (qualitative) defects
• Thrombin–antithrombin (TAT) complex measurement as an adjunctive marker of in vivo thrombin generation
• Interpretive panels combining antithrombin with prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, and D-dimer for DIC evaluation
• Antithrombin stability and recovery studies in plasma-derived product characterization

Testing Methods

Chromogenic (Amidolytic) Substrate Assay

The reference method for functional antithrombin determination is the chromogenic amidolytic assay, performed on automated coagulation analyzers or microplate readers. In the presence of excess heparin, diluted test plasma is incubated with a fixed excess of bovine thrombin or activated factor Xa. Antithrombin in the sample neutralizes a stoichiometric proportion of the enzyme; the residual enzyme then cleaves a synthetic chromogenic substrate (such as a thrombin- or Xa-specific p-nitroaniline substrate), releasing p-nitroaniline. Absorbance measured at 405 nm is inversely proportional to the antithrombin activity in the original sample, which is quantified against a multi-point calibration curve traceable to species-specific or international reference material.

Immunologic Assays

Immunoturbidimetric, nephelometric, and sandwich ELISA methods quantify antithrombin antigen rather than function. These assays depend on antibodies with demonstrated cross-reactivity to the target species and are valuable for distinguishing hereditary quantitative deficiency from rare qualitative variants in which antigen is normal but activity is reduced. Because antigen assays do not detect functional defects, they should complement, not replace, chromogenic activity measurement.

Method Validation and Quality Control

Accredited third-party laboratories performing animal antithrombin testing establish and verify method performance under ISO/IEC 17025 quality systems. Key validation parameters include:

• Calibration linearity and accuracy traceable to species-specific pooled plasma or pharmacopoeial reference preparations
• Imprecision with intra-run and inter-run coefficients of variation typically below 10%
• Lower limit of quantification adequate for detecting severe deficiency states (activity below 30%)
• Interference assessment for hemolysis, lipemia, bilirubin, fibrin degradation products, and residual heparin
• Species-specific reference interval verification for dogs, cats, horses, cattle, and laboratory rodents
• Participation in interlaboratory comparison or proficiency testing programs where available

Where antithrombin testing supports potency release of biological products, compendial procedures described in major pharmacopoeias, including the Chinese Pharmacopoeia and the United States Pharmacopeia, are applied for heparin cofactor activity measurement under validated conditions.

Applications

Veterinary Clinical Diagnostics

Antithrombin activity is a cornerstone marker in the diagnostic evaluation of acquired and inherited coagulopathies. Decreased activity is characteristic of disseminated intravascular coagulation, in which antithrombin is consumed by ongoing thrombin generation, and serial monitoring helps stratify prognosis and guide plasma therapy. Inherited antithrombin deficiency has been documented in specific canine lines, and measurement enables diagnosis, carrier screening, and breeding guidance.

Hepatic, Renal, and Protein-Losing Disorders

Because antithrombin is hepatically synthesized, markedly reduced activity supports severe liver dysfunction or failure. Nephrotic syndrome and protein-losing enteropathy in dogs and cats cause urinary and enteric antithrombin loss, respectively, increasing thrombotic risk; activity determination quantifies this risk and informs prophylactic decisions.

Heparin Therapy Monitoring

Adequate antithrombin activity (generally above 70% of reference) is required for effective heparin anticoagulation. Animals with low antithrombin exhibit apparent heparin resistance, and measurement identifies candidates for antithrombin supplementation before or during heparinization in critically ill patients.

Preclinical Research and Biological Product Characterization

• Pharmacodynamic and safety evaluation of anticoagulant, procoagulant, and prothrombotic drug candidates in animal models
• Thrombosis, sepsis, and inflammation research utilizing rodent and large-animal models
• Potency and consistency testing of plasma-derived antithrombin concentrates and intermediates
• Comparative physiology studies investigating species and breed variation in coagulation regulation

FAQ

What does a low antithrombin activity result indicate in an animal? Reduced activity most commonly reflects consumption in DIC, impaired hepatic synthesis, or loss through the kidneys or gastrointestinal tract. Hereditary deficiency, although rare, is documented in certain canine breeds. Results must always be interpreted alongside species- and breed-appropriate reference intervals and the full coagulation profile.

Can human antithrombin assay kits be used directly for animal samples? Chromogenic activity assays are generally applicable across species when validated with species-matched calibrators and reference intervals. Immunologic antigen assays, however, depend on antibody cross-reactivity and must be verified for each species before reporting. Accredited third-party laboratories confirm species applicability during method validation.

How should samples be stored before testing? Citrated platelet-poor plasma should be separated promptly, kept at 2–8 °C if tested within 24 hours, or frozen at −70 °C or below for extended storage. Freeze–thaw cycles must be minimized, and clotted or heparin-contaminated specimens should be recollected.

What is the difference between antithrombin activity and antigen assays? Activity assays measure functional inhibitory capacity against thrombin or factor Xa and detect both quantitative and qualitative deficiencies. Antigen assays measure protein mass immunologically and may miss functional variants; combining both distinguishes the deficiency type.

How are results reported? Activity is reported as a percentage of species-specific pooled reference plasma or in IU/mL, accompanied by the laboratory's validated reference interval, methodology, and interpretive commentary. Critical results indicating severe deficiency or heparin resistance are communicated promptly to support clinical decision-making.